FDA advisors recommend approval of taxol for node-positive breast cancer.
D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D017277:Drug Approval; D005260:Female; D006801:Humans; D008207:Lymphatic Metastasis; D017239:Paclitaxel / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration
D000972:Antineoplastic Agents, Phytogenic; D017239:Paclitaxel